<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2026.670</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-2707</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ОRIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>Predicting chronic placental insufficiency in patients with a complicated obstetric history at pregnancy planning stage</article-title><trans-title-group xml:lang="ru"><trans-title>Прогнозирование развития хронической плацентарной недостаточности у пациенток с отягощенным акушерским анамнезом на этапе планирования беременности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4512-9599</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремеева</surname><given-names>Д. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremeeva</surname><given-names>D. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Еремеева Дина Рустемовна - к.м.н.</p><p>Scopus Author ID: 57201320518</p><p>Wos ResearcherID: ODL-0454-2025</p><p>eLibrary SPIN-code: 8272-0950</p><p>197022 Санкт-Петербург, ул. Льва Толстого, д. 6/8; 192014 Санкт-Петербург, ул. Маяковского, д. 5; 195271 Санкт-Петербург, Кондратьевский проспект, д. 72А</p></bio><bio xml:lang="en"><p>Dina R. Eremeeva - MD, PhD.</p><p>Scopus Author ID: 57201320518</p><p>Wos ResearcherID: ODL-0454-2025</p><p>eLibrary SPIN-code: 8272-0950</p><p>6/8 Lev Tolstoy Str., Saint Petersburg 197022; 5 Mayakovskogo Str., Saint Petersburg 192014; 72А Kondratievsky Prospekt, Saint Petersburg 195271</p></bio><email xlink:type="simple">dina-bikmullina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2622-5000</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайнулина</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zainulina</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зайнулина Марина Сабировна - д.м.н., проф.</p><p>Scopus Author ID: 37076359000</p><p>Wos ResearcherID: B-5746-2018</p><p>eLibrary SPIN-code: 3955-8429</p><p>197022 Санкт-Петербург, ул. Льва Толстого, д. 6/8; 192014 Санкт-Петербург, ул. Маяковского, д. 5; 195271 Санкт-Петербург, Кондратьевский проспект, д. 72А</p></bio><bio xml:lang="en"><p>Marina S. Zainulina - MD, Dr Sci Med, Prof.</p><p>Scopus Author ID: 37076359000</p><p>Wos ResearcherID: B-5746-2018</p><p>eLibrary SPIN-code: 3955-8429</p><p>6/8 Lev Tolstoy Str., Saint Petersburg 197022; 5 Mayakovskogo Str., Saint Petersburg 192014; 72А Kondratievsky Prospekt, Saint Petersburg 195271</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации; СПб ГБУЗ «Родильный дом № 6 имени профессора В.Ф. Снегирева»; ЧОУ ВО «Санкт-Петербургский медико-социальный институт»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation; Snegirev Maternity Hospital No 6; Saint Petersburg Medical and Social Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2026</year></pub-date><volume>20</volume><issue>1</issue><fpage>51</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Eremeeva D.R., Zainulina M.S., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Еремеева Д.Р., Зайнулина М.С.</copyright-holder><copyright-holder xml:lang="en">Eremeeva D.R., Zainulina M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/2707">https://www.gynecology.su/jour/article/view/2707</self-uri><abstract><sec><title>Introduction</title><p>Introduction. Chronic placental insufficiency (CPI) is one of the leading causes of fetal growth restriction (FGR), perinatal loss, and complicated pregnancy. Currently, no validated methods for predicting CPI during pregnancy planning are available, which complicates high-risk patient stratification early and enabling timely prevention.</p></sec><sec><title>Aim</title><p>Aim: to develop a mathematical model for predicting CPI risk in women with a complicated obstetric history at the pre-pregnancy preparation stage.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. A retrospective clinical study assessing 462 patients with a complicated obstetric history was conducted. The outcomes of previous pregnancies, concomitant extragenital diseases, circulation of criterial (anti-β2glycoprotein and anti-cardiolipin antibodies, lupus anticoagulant) and non-criterial (anti-annexin 5, anti-phosphatidylserine, anti-phosphatidylinositol, anti-prothrombin, anti-human chorionic gonadotropin) antiphospholipid antibodies (APA), indicators of lymphocyte subpopulation composition, coagulation profile, and genetic thrombophilia were evaluated. Enzyme-linked immunosorbent assay, flow cytometry, ultrasound, and histological diagnostics were used. Binary logistic regression was applied to construct a prognostic model, and the diagnostic significance of the indicators was assessed using ROC curves.</p></sec><sec><title>Results</title><p>Results. Detected APA high titers and/or lupus anticoagulant were associated with significantly elevated CPI incidence (63.1% vs. 4.6%; p &lt; 0.001) and FGR (43.4% vs. 4.6%; p &lt; 0.001). Immunological imbalance (increased percentage of B-lymphocytes and NK cells) increased CPI risk by 1.3–5.5 times. The constructed prediction model, which included indicators of immunological activity and comorbidity, demonstrated high accuracy: AUC = 0.89, sensitivity 85.7%, specificity 85.7%.</p></sec><sec><title>Conclusion</title><p>Conclusion. The developed mathematical model allows for highly accurate prediction of CPI risk developing in women with a complicated obstetric history even before pregnancy, which opens up avenues for personalized selection of preventive measures, including immunomodulatory therapy and dynamic monitoring, and contributes to lowering frequency of perinatal complications.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Введение</title><p>Введение. Хроническая плацентарная недостаточность (ХПН) является одной из ведущих причин задержки роста плода (ЗРП), перинатальных потерь и осложненного течения беременности. На сегодняшний день отсутствуют валидированные методы прогнозирования ХПН на этапе планирования беременности, что затрудняет раннюю стратификацию пациенток группы риска и проведение своевременной профилактики.</p></sec><sec><title>Цель</title><p>Цель: разработать математическую модель прогнозирования риска развития ХПН у женщин с отягощенным акушерским анамнезом на этапе прегравидарной подготовки.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведено ретроспективное клиническое исследование, включившее 462 пациентки с осложненным акушерским анамнезом. Оценивались исходы предыдущих беременностей, сопутствующие экстрагенитальные заболевания, циркуляция критериальных (антитела к β2-гликопротеину, кардиолипину, волчаночный антикоагулянт) и некритериальных (к аннексину 5, фосфатидилсерину, фосфатидилинозитолу, протромбину, хорионическому гонадотропину человека) антифосфолипидных антител (АФА), показатели субпопуляционного состава лимфоцитов, коагуляционного профиля и генетической тромбофилии. Использованы методы иммуноферментного анализа, проточной цитометрии, ультразвуковой и гистологической диагностики. Для построения прогностической модели применяли бинарную логистическую регрессию, диагностическую значимость показателей оценивали по ROC-кривым.</p></sec><sec><title>Результаты</title><p>Результаты. Наличие высоких титров АФА и/или волчаночного антикоагулянта ассоциировалось со значимо более высокой частотой ХПН (63,1 % против 4,6 %; p &lt; 0,001) и ЗРП (43,4 % против 4,6 %; p &lt; 0,001). Иммунологический дисбаланс (повышение относительного содержания В-лимфоцитов и NK-клеток) повышал риск реализации ХПН в 1,3–5,5 раза. Построенная модель прогнозирования, включающая показатели иммунологической активности и коморбидности, продемонстрировала высокую точность: AUC = 0,89, чувствительность 85,7 %, специфичность 85,7 %.</p></sec><sec><title>Заключение</title><p>Заключение. Разработанная математическая модель позволяет с высокой точностью прогнозировать риск развития ХПН у женщин с отягощенным акушерским анамнезом еще до наступления беременности, что открывает возможности для персонализированного подбора профилактических мероприятий, в том числе иммуномодулирующей терапии и динамического наблюдения, и способствует снижению частоты перинатальных осложнений.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая плацентарная недостаточность</kwd><kwd>ХПН</kwd><kwd>прогнозирование</kwd><kwd>антифосфолипидные антитела</kwd><kwd>АФА</kwd><kwd>иммунологические маркеры</kwd><kwd>акушерские осложнения</kwd><kwd>математическая модель</kwd><kwd>планирование беременности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic placental insufficiency</kwd><kwd>CPI</kwd><kwd>prediction</kwd><kwd>antiphospholipid antibodies</kwd><kwd>APA</kwd><kwd>immunological markers</kwd><kwd>obstetric complications</kwd><kwd>mathematical model</kwd><kwd>pregnancy planning</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The authors declare no funding</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Савельева Г.М., Серов В.Н., Сухих Г.Т. Акушерство: национальное руководство. М.: ГЭОТАР-Медиа, 2022. 1080 p.</mixed-citation><mixed-citation xml:lang="en">Savelyeva G.M., Serov V.N., Sukhikh G.T. Obstetrics: national leadership. [Akusherstvo. Nacional'noe rukovodstvo]. Moscow: GEOTAR-Media, 2022. 1080 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mayrink J., Costa M.L., Cecatti J.G. Preeclampsia in 2018: revisiting concepts, physiopathology and prediction. Sci World J. 2018;2018(1):6268276. https://doi.org/10.1155/2018/6268276.</mixed-citation><mixed-citation xml:lang="en">Mayrink J., Costa M.L., Cecatti J.G. Preeclampsia in 2018: revisiting concepts, physiopathology and prediction. Sci World J. 2018;2018(1):6268276. https://doi.org/10.1155/2018/6268276.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Воронцова З.A., Жиляева О.Д., Золотарева С.Н., Логачева В.В. Экспериментальное моделирование плацентарной недостаточности и синдрома задержки роста плода (обзор литературы). Вестник новых медицинских технологий. 2021;15(1):35–46. https://doi.org/10.24412/2075-4094-2021-1-1-5.</mixed-citation><mixed-citation xml:lang="en">Vorontsova Z.A., Zhilyaeva O.D., Zolotareva S.N., Logacheva V.V. Experimental modeling of placental insufficiency and fetal growth retardation syndrome (literature review). [Eksperimental'noe modelirovanie placentarnoj nedostatochnosti i sindroma zaderzhki rosta ploda (obzor literatury). Vestnik novyh medicinskih tekhnologij. 2021;15(1):35–46. (In Russ.). https://doi.org/10.24412/2075-4094-2021-1-1-5. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Brosens I., Pijnenborg R., Vercruysse L., Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201. https://doi.org/10.1016/j.ajog.2010.08.009.</mixed-citation><mixed-citation xml:lang="en">Brosens I., Pijnenborg R., Vercruysse L., Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201. https://doi.org/10.1016/j.ajog.2010.08.009.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mifsud W., Sebire N.J. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther. 2014;36(2):117–28. https://doi.org/10.1159/000359969.</mixed-citation><mixed-citation xml:lang="en">Mifsud W., Sebire N.J. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther. 2014;36(2):117–28. https://doi.org/10.1159/000359969.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x.</mixed-citation><mixed-citation xml:lang="en">Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Branch D.W., Gibson M., Silver R.M. Recurrent miscarriage. N Engl J Med. 2010;363(18):1740–7. https://doi.org/10.1056/NEJMcp1005330.</mixed-citation><mixed-citation xml:lang="en">Branch D.W., Gibson M., Silver R.M. Recurrent miscarriage. N Engl J Med. 2010;363(18):1740–7. https://doi.org/10.1056/NEJMcp1005330.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Giannakopoulos B., Krilis S.A. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033–44. https://doi.org/10.1056/nejmra1112830.</mixed-citation><mixed-citation xml:lang="en">Giannakopoulos B., Krilis S.A. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033–44. https://doi.org/10.1056/nejmra1112830.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Оруджова Э.А., Самбурова Н.В., Аничкова Е.В. и др. Тромбофилии в патогенезе задержки роста плода. Акушерство, Гинекология и Репродукция. 2021;15(2):189–200. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.223.</mixed-citation><mixed-citation xml:lang="en">Orudzhova E.A., Samburova N.A., Anichkova E.V. et al. Thrombophilia in the pathogenesis of fetal growth retardation. [Trombofilii v patogeneze zaderzhki rosta ploda]. Obstetrics, Gynecology and Reproduction. 2021;15(2):189–200. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.223.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol. 2013;31:387–411. https://doi.org/10.1146/annurevimmunol-032712-100003.</mixed-citation><mixed-citation xml:lang="en">Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol. 2013;31:387–411. https://doi.org/10.1146/annurevimmunol-032712-100003.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Guleria I., Pollard J.W. The trophoblast is a component of the innate immune system during pregnancy. Nat Med. 2000;6(5):589–93. https://doi.org/10.1038/75074.</mixed-citation><mixed-citation xml:lang="en">Guleria I., Pollard J.W. The trophoblast is a component of the innate immune system during pregnancy. Nat Med. 2000;6(5):589–93. https://doi.org/10.1038/75074.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kwak J.Y.H., Beaman K.D., Gilman-Sachs A. et al. Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol. 1995;34(2):93–9. https://doi.org/10.1111/j.1600-0897.1995.tb00924.x.</mixed-citation><mixed-citation xml:lang="en">Kwak J.Y.H., Beaman K.D., Gilman-Sachs A. et al. Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol. 1995;34(2):93–9. https://doi.org/10.1111/j.1600-0897.1995.tb00924.x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hadlock F.P., Harrist R.B., Sharman R.S. et al. Estimation of fetal weight with the use of head, body, and femur measurements-a prospective study. Am J Obstet Gynecol. 1985;151(3):333–7. https://doi.org/10.1016/0002-9378(85)90298-4.</mixed-citation><mixed-citation xml:lang="en">Hadlock F.P., Harrist R.B., Sharman R.S. et al. Estimation of fetal weight with the use of head, body, and femur measurements-a prospective study. Am J Obstet Gynecol. 1985;151(3):333–7. https://doi.org/10.1016/0002-9378(85)90298-4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gordijn S.J., Beune I.M., Thilaganathan B. et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–9. https://doi.org/10.1002/uog.15884.</mixed-citation><mixed-citation xml:lang="en">Gordijn S.J., Beune I.M., Thilaganathan B. et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–9. https://doi.org/10.1002/uog.15884.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Павлова Н.Г., Аржанова О.Н., Зайнулина М.С., Колобов А.В. Плацентарная недостаточность: учебно-методическое пособие. СПб, 2007. 28 с.</mixed-citation><mixed-citation xml:lang="en">Pavlova N.G., Arzhanova O.N., Zainulina M.S., Kolobov A.V. Placental insufficiency: educational and methodological manual. [Placentarnaya nedostatochnost': uchebno-metodicheskoe posobie]. Saint Petersburg, 2007. 28 р. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Игнатко И.В., Денисова Ю.В., Филиппова Ю.А., Дубинин А.О. Дифференциальная диагностика ранней и поздней форм синдрома задержки развития плода. Уральский медицинский журнал. 2020;(12):91–7. https://doi.org/10.25694/URMJ.2020.12.22.</mixed-citation><mixed-citation xml:lang="en">Ignatko I.V., Denisova Yu.V., Filippova Yu.A., Dubinin A.O. Differential diagnosis of early and late forms of fetal delay syndrome. [Differencial'naya diagnostika rannej i pozdnej form sindroma zaderzhki razvitiya ploda]. Ural'skij medicinskij zhurnal. 2020;(12):91–7. (In Russ.). https://doi.org/10.25694/URMJ.2020.12.22.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Чехонин В.П., Гурина О.И., Дмитриева Т.Б. Моноклональные антитела к нейроспецифическим белкам. М.: Медицина, 2007. 344 с.</mixed-citation><mixed-citation xml:lang="en">Chekhonin V.P., Gurina O.I., Dmitrieva T.B. Monoclonal antibodies to neurospecific proteins. [Monoklonal'nye antitela k nejrospecificheskim belkam]. Moscow: Medicina, 2007. 344 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Erkan D., Aguiar C.L., Andrade D. et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. https://doi.org/10.1016/j.autrev.2014.01.</mixed-citation><mixed-citation xml:lang="en">Erkan D., Aguiar C.L., Andrade D. et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. https://doi.org/10.1016/j.autrev.2014.01.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tong M., Johansson C., Xiao F. et al. Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia. Sci Rep. 2017;7:16556. https://doi.org/10.1038/s41598-017-16448-5.</mixed-citation><mixed-citation xml:lang="en">Tong M., Johansson C., Xiao F. et al. Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia. Sci Rep. 2017;7:16556. https://doi.org/10.1038/s41598-017-16448-5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tong M., Viall C.A., Chamley L.W. Antiphospholipid antibodies and the placenta: A systematic review of their In vitro effects and modulation by treatment. Hum Reprod Update. 2015;21(1):97–118. https://doi.org/10.1093/humupd/dmu049.</mixed-citation><mixed-citation xml:lang="en">Tong M., Viall C.A., Chamley L.W. Antiphospholipid antibodies and the placenta: A systematic review of their In vitro effects and modulation by treatment. Hum Reprod Update. 2015;21(1):97–118. https://doi.org/10.1093/humupd/dmu049.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hoxha A., Tormene D., Campello E., Simioni P. Treatment of refractory/ high-risk pregnancies with antiphospholipid syndrome: a systematic review of the literature. Front Pharmacol. 2022;13:849692. https://doi.org/10.3389/fphar.2022.849692.</mixed-citation><mixed-citation xml:lang="en">Hoxha A., Tormene D., Campello E., Simioni P. Treatment of refractory/ high-risk pregnancies with antiphospholipid syndrome: a systematic review of the literature. Front Pharmacol. 2022;13:849692. https://doi.org/10.3389/fphar.2022.849692.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Moore J.M., Nahlen B.L., Lal A.A., Udhayakumar V. Immunologic memory in the placenta: a lymphocyte recirculation hypothesis. Med Hypotheses. 2000;54(3):505–10. https://doi.org/10.1054/mehy.1999.0888.</mixed-citation><mixed-citation xml:lang="en">Moore J.M., Nahlen B.L., Lal A.A., Udhayakumar V. Immunologic memory in the placenta: a lymphocyte recirculation hypothesis. Med Hypotheses. 2000;54(3):505–10. https://doi.org/10.1054/mehy.1999.0888.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Racicot K., Kwon J.Y., Aldo P. et al. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol. 2014;72(2):107–16. https://doi.org/10.1111/aji.12289.</mixed-citation><mixed-citation xml:lang="en">Racicot K., Kwon J.Y., Aldo P. et al. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol. 2014;72(2):107–16. https://doi.org/10.1111/aji.12289.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dekker G.A. Risk factors for preeclampsia. Clin Obstet Gynecol. 1999;42(3):422. https://doi.org/10.1097/00003081-199909000-00002.</mixed-citation><mixed-citation xml:lang="en">Dekker G.A. Risk factors for preeclampsia. Clin Obstet Gynecol. 1999;42(3):422. https://doi.org/10.1097/00003081-199909000-00002.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Tong M., Abrahams V.M. Immunology of the рlacenta. Obstet Gynecol Clin North Am. 2020;47(1):49–63. https://doi.org/10.1016/j.ogc.2019.10.006.</mixed-citation><mixed-citation xml:lang="en">Tong M., Abrahams V.M. Immunology of the рlacenta. Obstet Gynecol Clin North Am. 2020;47(1):49–63. https://doi.org/10.1016/j.ogc.2019.10.006.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Tong M., Kayani T., Jones D.M. et al. Antiphospholipid antibodies increase endometrial stromal cell decidualization, senescence, and inflammation via toll-like receptor 4, reactive oxygen species, and p38 MAPK signaling. Arthritis Rheumatol. 2022;74(6):1001–12. https://doi.org/10.1002/art.42068.</mixed-citation><mixed-citation xml:lang="en">Tong M., Kayani T., Jones D.M. et al. Antiphospholipid antibodies increase endometrial stromal cell decidualization, senescence, and inflammation via toll-like receptor 4, reactive oxygen species, and p38 MAPK signaling. Arthritis Rheumatol. 2022;74(6):1001–12. https://doi.org/10.1002/art.42068.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Еремеева Д.Р., Зайнулина М.С. Оценка эффективности профилактики плацента-ассоциированных осложнений у пациенток с отягощенным акушерским анамнезом и циркуляцией антифосфолипидных антител. Акушерство, Гинекология и Репродукция. 2024;18(4):475–91. https://doi.org/10.17749/23137347/ob.gyn.rep.2024.479.</mixed-citation><mixed-citation xml:lang="en">Eremeeva D.R., Zainulina M.S. Assessing the effectiveness of preventing placenta-associated complications in patients with burdened obstetric history and circulating antiphospholipid antibodies. [Otsenka effektivnosti profilaktiki platsenta-assotsiirovannykh oslozhnenii u patsientok s otiazhchennym akusherskim anamnezom i tsirkuliatsiei antifosfolipidnykh antitel]. Obstetrics, Gynecology and Reproduction. 2024;18(4):475–91. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.479.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kornacki J., Gutaj P., Kalantarova A. et al. Endothelial dysfunction in pregnancy complications. Biomedicines. 2021;9(12):1756. https://doi.org/10.3390/biomedicines9121756.</mixed-citation><mixed-citation xml:lang="en">Kornacki J., Gutaj P., Kalantarova A. et al. Endothelial dysfunction in pregnancy complications. Biomedicines. 2021;9(12):1756. https://doi.org/10.3390/biomedicines9121756.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Egerup P., Lindschou J., Gluud C. et al. The effects of intravenous immunoglobulins in women with recurrent miscarriages: a systematic review of randomised trials with meta-analyses and trial sequential analyses including individual patient data. PLoS One. 2015;10(10):e0141588. https://doi.org/10.1371/journal.pone.0141588.</mixed-citation><mixed-citation xml:lang="en">Egerup P., Lindschou J., Gluud C. et al. The effects of intravenous immunoglobulins in women with recurrent miscarriages: a systematic review of randomised trials with meta-analyses and trial sequential analyses including individual patient data. PLoS One. 2015;10(10):e0141588. https://doi.org/10.1371/journal.pone.0141588.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Tektonidou M.G., Andreoli L., Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296–1304. https://doi.org/10.1136/annrheumdis-2019-215213.</mixed-citation><mixed-citation xml:lang="en">Tektonidou M.G., Andreoli L., Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296–1304. https://doi.org/10.1136/annrheumdis-2019-215213.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gao R., Qin L. Correspondence on “EULAR recommendations for the management of antiphospholipid syndrome in adults”. Ann Rheum Dis. 2023;82(5):e107. https://doi.org/10.1136/annrheumdis-2021-220092.</mixed-citation><mixed-citation xml:lang="en">Gao R., Qin L. Correspondence on “EULAR recommendations for the management of antiphospholipid syndrome in adults”. Ann Rheum Dis. 2023;82(5):e107. https://doi.org/10.1136/annrheumdis-2021-220092.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
